Centessa Begins Narcolepsy Drug Candidate ORX750 Trials

Centessa recently initiated the phase 1 clinical trial of ORX750, an orexin receptor 2 agonist in development for narcolepsy treatment.

Related Keywords

Saurabh Saha ,Centessa Pharmaceuticals ,Drug Administration ,Investigational New Drug ,Chief Executive Officer ,